담관암에 있어서 분자생물학적 측면과 종양표지자들의 역할 = Special Review : Molecular pathogenesis and the role of tumor markers in cholangiocarcinoma

다국어 초록 (Multilingual Abstract)

Cholangiocarcinoma is a devastating cancer originating from the epithelial cell lining of the bile duct, whose prognosis is poor due to suboptimal response to therapy despite the fact that the incidence is increasing. Hence surgery still remains the only curative treatment option for cholangiocarcinoma. Recent investigations into the underlying biochemical and molecular mechanisms in biliary carcinogenesis and tumor growth, may illuminate new therapeutic modalities and suggest some new serum and bile markers that could be useful for the diagnosis of cholangiocarcinoma. In this review, we discuss the molecular mechanisms of pathogenesis in cholangiocarcinoma and the role of new tumor makers for the diagnosis of cholangiocarcinoma. (Korean J Med 79:597-604, 2010)

참고문헌 (Reference)

1 Wang Y, "Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K-ras mutation" 37 : 831-839, 2002

2 Benckert C, "Transfoming growth factor beta 1 stimulates vascular endothelial growth factor gene transcrtiption in human cholangiocellular carcinoma cells" 63 : 1083-1092, 2003

3 Williams CS, "The role of cyclooxygenases in inflammation, cancer and development" 18 : 7908-7916, 1999

4 Hejna M, "The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature" 34 : 977-986, 1998

5 Berthiaume EP, "The molecular pathogenesis of cholangiocarcinoma" 24 : 127-137, 2004

6 Hanahan D, "The hallmarks of cancer" 100 : 57-70, 2000

7 Jarnagin WR, "Staging, resectability,and outcome in 225 patients with hilar cholangiocarcinoma" 234 : 507-519, 2001

8 Uenishi T, "Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma" 15 : 583-589, 2008

9 Alvaro D, "Serum andbiliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis" 147 : 451-459, 2007

10 Nehls O, "Serum and bile markers for cholangiocarcinoma" 24 : 139-154, 2004

11 Alvaro D, "Serum and bile biomarkers for cholangiocarcinoma" 25 : 279-284, 2009

12 Klump B, "Promoter methylation of INK4a/ARF as detected in bile-significance for differential diagnosis in biliary disease" 9 : 1773-1778, 2003

13 Briggs CD, "Prognostic molecular markers in cholangiocarcinoma: a systematic review" 45 : 33-47, 2009

14 Lavaissiere L, "Overexpression of human aspartyl (asparaginyl) beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma" 98 : 1313-1323, 1996

15 Török NJ, "Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9" 62 : 1648-1653, 2002

16 Fava G, "Molecular pathology of biliary tract cancers" 250 : 155-167, 2007

17 Green DR, "Mitochondria and apoptosis" 281 : 1309-1312, 1998

18 Goydos JS, "Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker" 227 : 398-404, 1998

19 Matull WR, "MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer" 98 : 1675-1681, 2008

20 Van Heek NT, "Long-term follow-up of patients with clinically benign extrahepatic biliary stenosis and K-ras mutation in endobiliary brush cytology" 55 : 883-888, 2002

21 Kubicka S, "K-ras mutations in the bile of patients with primary sclerosing cholangitis" 48 : 403-408, 2001

22 Park J, "Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line" 30 : 1128-1133, 1999

23 Patel T, "Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States" 33 : 1353-1357, 2001

24 Rumalla A, "Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis" 76 : 29-33, 2001

25 Matsumoto K, "Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro" 20 : 376-382, 1994

26 Yokomuro S, "Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic bilieary epithelial cells" 32 : 26-35, 2000

27 Tannapfel A, "Frequency of p16-INK4A alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver" 47 : 721-727, 2000

28 Terada T, "Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors" 23 : 1341-1344, 1996

29 Lempinen M, "Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures" 47 : 677-683, 2007

30 Ong SL, "Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration" 53 : 3213-3217, 2008

31 Cheon YK, "Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy" 102 : 2164-2170, 2007

32 Chen CY, "Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis" 390 : 82-89, 2008

33 Ayaru L, "Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates" 98 : 1548-1554, 2008

34 Sirica AE, "Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets" 22 : 303-313, 2002

35 Kiguchi K, "Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma" 61 : 6971-6976, 2001

36 Ryan ME, "Comparison of flow cytometry for DNA content and brush cytology for detection of malignancy in pancreaticobiliary strictures" 40 : 133-139, 1994

37 Sturm PD, "Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis" 5 : 629-635, 1999

38 Bonney GK, "Circulating markers of biliary malignancy: opportunities in proteomics?" 9 : 149-158, 2008

39 Lipsett PA, "Choledochal cyst disease: a changing pattern of presentation" 220 : 644-652, 1994

40 Que FG, "Cholangiocarcinomas express Fas ligand and disable the Fasreceptor" 30 : 1398-1404, 1999

41 Davila JA, "Cholangiocarcinoma: the ‘‘other’’ liver cancer on the rise" 97 : 3199-3200, 2002

42 Okuda K, "Cholangiocarcinoma: recent progress: part 2. molecular pathology and treatment" 17 : 1056-1063, 2002

43 Gores GJ, "Cholangiocarcinoma: current concepts and insights" 37 : 961-969, 2003

44 Blechacz B, "Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment" 48 : 308-321, 2008

45 Rashid A, "Cellular and molecular biology of biliary tract cancers" 11 : 995-1009, 2002

46 Parker SL, "Cancer statistics, 1996" 46 : 5-27, 1996

47 Nzeako UC, "COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells" 35 : 552-559, 2002

48 De Groen PC, "Biliary tract cancers" 341 : 1368-1378, 1999

49 Yoon JH, "Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line" 122 : 985-993, 2002

50 Laurent-Puig P, "Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases" 36 : 455-458, 1995

51 Belinsky SA, "Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential bio marker for early diagnosis" 95 : 11891-11896, 1998

52 Kim HJ, "A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve" 94 : 1941-1946, 1999

53 Bamrungphon W, "A new mucin antibody/ enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma" 247 : 301-308, 2007